Oliver Schilling
Principal Investigator
Institute of Surgical Pathology
Medical Center University of Freiburg
Breisacher Straße 115a
79106 Freiburg
- +49 761 270-80610
- oliver.schilling@uniklinik-freiburg.de
- Homepage
Current position
Academic training
| 1994 - 2000 | Studies in Biology in Münster, Germany, and Tours, France (Diplom-Biologe and Licence de Biochimie) |
Advanced academic qualifications
| 2014 | Habilitation (Venia Legendi) in Molecular Medicine, University of Freiburg |
| 2004 | Doctorate (Dr. rer. nat.), University of Münster and European Molecular Biology Laboratory |
Postgraduate positions
| Since 2018 | Heisenberg Professor for Translational Proteome Research at the Institute of Surgical Pathology, University Freiburg Medical Center |
| 2008 - 2018 | Research group leader, Institute of Molecular Medicine and Cell Research, University of Freiburg |
| 2005 - 2008 | Postdoctoral fellow, University of British Columbia, Vancouver, Canada |
| 2004 | Postdoctoral fellow, European Molecular Biology Laboratory Hamburg/Heidelberg |
| 2000 - 2004 | International PhD program, European Molecular Biology Laboratory Hamburg/Heidelberg |
Miscellaneous (Honors, Awards)
| 2017 | Heisenberg professorship of the DFG |
| 2012 - 2017 | Starting Grant of the European Research Council ERC |
| 2009 - 2014 | Emmy-Noether funding of the DFG |
Publications listed in PubMed®
Publications (based on CRC1479 funding)
Kocsmár É, Schmid M, Cosenza-Contreras M, Kocsmár I, Föll M, Krey L, Barta BA, Rácz G, Kiss A, Werner M, Schilling O, Lotz G, Bronsert P. Proteome alterations in human autopsy tissues in relation to time after death. Cell Mol Life Sci. 2023 Apr 5;80(5):117. doi: 10.1007/s00018-023-04754-3.
Stillger MN, Chen CY, Lai ZW, Li M, Schäfer A, Pagenstecher A, Nimsky C, Bartsch JW, Schilling O. Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis. Cancer Cell Int. 2023 Mar 17;23(1):49. doi: 10.1186/s12935-023-02889-8.
Werner J, Bernhard P, Cosenza-Contreras M, Pinter N, Fahrner M, Pallavi P, Eberhard J, Bronsert P, Rückert F, Schilling O. Targeted and explorative profiling of kallikrein proteases and global proteome biology of pancreatic ductal adenocarcinoma, chronic pancreatitis, and normal pancreas highlights disease-specific proteome remodelling. Neoplasia. 2023 Feb;36:100871. doi: 10.1016/j.neo.2022.100871. Epub 2023 Jan 5.
Koistinen H, Kovanen RM, Hollenberg MD, Dufour A, Radisky ES, Stenman UH, Batra J, Clements J, Hooper JD, Diamandis E, Schilling O, Rannikko A, Mirtti T. The roles of proteases in prostate cancer. IUBMB Life. 2023 Jun;75(6):493-513. doi: 10.1002/iub.2700. Epub 2023 Jan 4.
Bernhard P, Feilen T, Rogg M, Fröhlich K, Cosenza-Contreras M, Hause F, Schell C, Schilling O. Proteome alterations during clonal isolation of established human pancreatic cancer cell lines. Cell Mol Life Sci. 2022 Oct 22;79(11):561. doi: 10.1007/s00018-022-04584-9.
Fröhlich K, Brombacher E, Fahrner M, Vogele D, Kook L, Pinter N, Bronsert P, Timme-Bronsert S, Schmidt A, Bärenfaller K, Kreutz C, Schilling O. Benchmarking of analysis strategies for data-independent acquisition proteomics using a large-scale dataset comprising inter-patient heterogeneity. Nat Commun. 2022 May 12;13(1):2622. doi: 10.1038/s41467-022-30094-0.
Pinter N, Glätzer D, Fahrner M, Fröhlich K, Johnson J, Grüning BA, Warscheid B, Drepper F, Schilling O, Föll MC. MaxQuant and MSstats in Galaxy Enable Reproducible Cloud-Based Analysis of Quantitative Proteomics Experiments for Everyone. J Proteome Res. 2022 May 3. doi: 10.1021/acs.jproteome.2c00051.
Contact
